DK1553952T3 - Anvendelse af dihydroimidazoloner til behandling af epilepsi hos hunde - Google Patents

Anvendelse af dihydroimidazoloner til behandling af epilepsi hos hunde

Info

Publication number
DK1553952T3
DK1553952T3 DK03757945T DK03757945T DK1553952T3 DK 1553952 T3 DK1553952 T3 DK 1553952T3 DK 03757945 T DK03757945 T DK 03757945T DK 03757945 T DK03757945 T DK 03757945T DK 1553952 T3 DK1553952 T3 DK 1553952T3
Authority
DK
Denmark
Prior art keywords
dihydroimidazolones
epilepsy
dogs
treatment
Prior art date
Application number
DK03757945T
Other languages
English (en)
Inventor
Rita Dost
Wolfgang Loescher
Andrea Tipold
Klaus Unverferth
Hans-Joachim Lankau
Chris Rundfeldt
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of DK1553952T3 publication Critical patent/DK1553952T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
DK03757945T 2002-10-10 2003-10-09 Anvendelse af dihydroimidazoloner til behandling af epilepsi hos hunde DK1553952T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (1)

Publication Number Publication Date
DK1553952T3 true DK1553952T3 (da) 2009-04-20

Family

ID=32094042

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03757945T DK1553952T3 (da) 2002-10-10 2003-10-09 Anvendelse af dihydroimidazoloner til behandling af epilepsi hos hunde
DK14191084.4T DK2845594T3 (da) 2002-10-10 2003-10-09 Anvendelse af dihydroimidazoloner til behandlingen af hunde.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14191084.4T DK2845594T3 (da) 2002-10-10 2003-10-09 Anvendelse af dihydroimidazoloner til behandlingen af hunde.

Country Status (28)

Country Link
US (5) US20050070537A1 (da)
EP (3) EP1553952B1 (da)
JP (4) JP4694202B2 (da)
KR (2) KR101110587B1 (da)
CN (2) CN101890019A (da)
AR (1) AR041573A1 (da)
AT (1) ATE418337T1 (da)
AU (2) AU2003273978B2 (da)
BE (1) BE2013C046I2 (da)
BR (1) BR0315225A (da)
CA (2) CA2501772C (da)
CY (3) CY1109961T1 (da)
DE (1) DE60325496D1 (da)
DK (2) DK1553952T3 (da)
ES (2) ES2316808T3 (da)
FR (2) FR13C0044I2 (da)
HK (1) HK1085920A1 (da)
HR (3) HRP20090667B1 (da)
HU (2) HUS1300035I1 (da)
LU (1) LU92238I2 (da)
MX (1) MXPA05003663A (da)
NZ (1) NZ539864A (da)
PL (2) PL214702B1 (da)
PT (2) PT1553952E (da)
SI (2) SI1553952T1 (da)
TW (2) TWI324067B (da)
WO (1) WO2004032938A1 (da)
ZA (1) ZA200502245B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
AU2004255414A1 (en) * 2003-07-11 2005-01-20 Boehringer Ingelheim Vetmedica Gmbh Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
EP3150598B1 (en) 2014-05-28 2019-02-13 TOA Eiyo Ltd. Substituted tropane derivatives
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de) * 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) * 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
JP2002507211A (ja) * 1997-06-26 2002-03-05 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ジヒドロホノキオール組成物の合成
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
EP1485094B2 (de) 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
HUS1300035I1 (hu) 2017-10-30
HRP20090667A2 (hr) 2010-07-31
JP2014080449A (ja) 2014-05-08
JP2011068685A (ja) 2011-04-07
US20130065898A1 (en) 2013-03-14
US8962617B2 (en) 2015-02-24
AU2003273978B2 (en) 2009-07-23
BE2013C046I2 (da) 2022-08-09
EP2845594B1 (en) 2022-02-23
LU92238I2 (fr) 2013-09-03
EP1553952A1 (en) 2005-07-20
KR20050056237A (ko) 2005-06-14
NZ539864A (en) 2007-11-30
ES2908453T3 (es) 2022-04-29
WO2004032938A1 (en) 2004-04-22
FR22C1033I1 (fr) 2022-09-09
CY1109961T1 (el) 2014-09-10
US20150072983A1 (en) 2015-03-12
DK2845594T3 (da) 2022-03-07
PL214702B1 (pl) 2013-09-30
HRP20200207A2 (hr) 2020-07-24
BR0315225A (pt) 2005-08-23
US9469611B2 (en) 2016-10-18
CY1125103T1 (el) 2023-01-05
KR20110063843A (ko) 2011-06-14
ATE418337T1 (de) 2009-01-15
ES2316808T3 (es) 2009-04-16
ZA200502245B (en) 2005-11-30
CN1726040B (zh) 2010-05-12
SI1553952T1 (sl) 2009-04-30
CA2727722A1 (en) 2004-04-22
DE60325496D1 (de) 2009-02-05
US8859540B2 (en) 2014-10-14
FR13C0044I2 (fr) 2014-03-07
PL374603A1 (en) 2005-10-31
AU2003273978A1 (en) 2004-05-04
TWI424849B (zh) 2014-02-01
HRP20050322A2 (en) 2006-05-31
AU2009225322A1 (en) 2009-11-05
FR13C0044I1 (da) 2013-08-30
US20080027057A1 (en) 2008-01-31
PT2845594T (pt) 2022-03-09
MXPA05003663A (es) 2005-06-08
CA2727722C (en) 2013-05-28
JP2006503873A (ja) 2006-02-02
US20160367562A1 (en) 2016-12-22
HRP20050322B1 (hr) 2013-12-06
CY2013031I1 (el) 2015-11-04
CN101890019A (zh) 2010-11-24
EP1553952B1 (en) 2008-12-24
CN1726040A (zh) 2006-01-25
CA2501772A1 (en) 2004-04-22
TWI324067B (en) 2010-05-01
AR041573A1 (es) 2005-05-18
HK1085920A1 (en) 2006-09-08
JP2016104817A (ja) 2016-06-09
HRP20090667B1 (hr) 2021-06-11
CA2501772C (en) 2011-08-23
TW201010706A (en) 2010-03-16
HUS2200036I1 (hu) 2022-08-28
CY2013031I2 (el) 2015-11-04
EP2845594A1 (en) 2015-03-11
LU92238I9 (da) 2019-01-09
PT1553952E (pt) 2009-02-10
EP2036563A1 (en) 2009-03-18
PL397320A1 (pl) 2012-02-13
SI2845594T1 (sl) 2022-04-29
PL238776B1 (pl) 2021-10-04
TW200503726A (en) 2005-02-01
KR101110587B1 (ko) 2012-02-15
JP4694202B2 (ja) 2011-06-08
US20050070537A1 (en) 2005-03-31
JP6249812B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
DK1474420T3 (da) Quinazolinforbindelser
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DE60319273D1 (de) Entzunderungsdüse
DE602004002966D1 (de) Spritzdüse
DK1667992T3 (da) Quinazolinderivater
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DE602004027504D1 (de) Aminobenzophenonverbindungen
CY2013031I1 (el) Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
ATE379983T1 (de) Klettverschluss
DK1638502T3 (da) Dentalt behandlingselement
NO20050689L (no) Terapeutisk anvendelse
DE60315063D1 (de) Elektrokontaktelement
DK1678085T3 (da) Fluidbehandlingsindretning
DE60311073D1 (de) Belüftungseinrichtung
ATE442835T1 (de) Oberflächenbehandlung
DE502004009781D1 (de) Einspritzventil
DE502004005095D1 (de) Einspritzdüse
DE60229887D1 (de) Oberflächenbehandlungssystem
DE10394115D2 (de) Schabewärmetauscher
NO20053898D0 (no) Use and proceeding at footballshoes
DK1636140T3 (da) Mindre enhed til behandling af spildevand
FI20021882A0 (fi) Jäteveden puhdistamo
NO20031166D0 (no) Behandlingsmetode
NO20034256D0 (no) Behandlingsmetode
NO20024831D0 (no) Behandlingsmetode